Alpha Cognition (ACOG) and China Medical System announced an exclusive licensing agreement for the development, manufacturing and commercialization of Zunveyl in Asia, Australia and New Zealand. Zunveyl is a next generation acetylcholinesterase inhibitor approved in the U.S. for the treatment of mild-to-moderate Alzheimer’s disease. Terms of the agreement total $44M, which includes $6M in total upfront payments split into tranches and development and commercial milestone payments. Additionally, ACI is eligible to receive royalties on net sales of Zunveyl in Asia, Australia and New Zealand. CMS will be responsible for the regulatory, development, manufacturing, and commercialization of Zunveyl in the licensed territories.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ACOG:
- Alpha Cognition files to sell 1.45M common shares for holders
- Alpha Cognition Raises $52.8 Million in Stock Offering
- Alpha Cognition Reports Promising Data for Brain Injury Drug
- Alpha Cognition voluntarily delisting from Canadian Securities Exchange
- Alpha Cognition: Data support ALPHA-1062 develpment for militaryTBI treatment